View article

Reporting research and development together implies their allocation provides limited insight to investors. We construct and corroborate unique measures of development and research to evaluate this aggregation. These measures combined correlate with reported R&D expenditures at 99%(industry) and 81%(firm). In the individual measure validation tests, our research measure correlates with scientific publications (77%), while the development measure correlates with patents (71%). Our R&D measures cover 76% of NYSE firms, providing broader coverage than patents (30%), new product announcements (20%), and reported expenditures (46%).